Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
19 sept. 2024 13h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in...
Oculis to Present at Upcoming September Investor Conferences
29 août 2024 04h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Publishes Consolidated Q2 Financial Statements and MD&A
27 août 2024 16h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Following the Company‘s press release published earlier today, the Q2 Consolidated Financial Statements and the MD&A, which have now been...
Oculis birtir uppgjör fyrir annan ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
27 août 2024 04h00 HE
|
Oculis Holding AG
ZUG, Sviss, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Félagið birti jákvæðar niðurstöður fyrir fasa 2b RELIEF rannsóknina á OCS-02 (licaminlimab) sem rennir stoðum undir möguleika á fyrstu...
Oculis Reports Q2 Financial Results and Provides Recent Company Update
27 août 2024 04h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision...
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
27 août 2024 04h00 HE
|
Oculis Holding AG
Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED)Phase 2 ACUITY trial of...
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
15 août 2024 08h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
15 août 2024 08h00 HE
|
Oculis Holding AG
Dr. Klier brings significant experience in ophthalmology and drug development with a proven track record in U.S. FDA approvals, which will be instrumental as the company advances its late-stage...
Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
30 juil. 2024 16h10 HE
|
Oculis Holding AG
ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis and EURETINA Announces the Ramin Tadayoni Award
27 juin 2024 06h30 HE
|
Oculis Holding AG
ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and...